Loading organizations...
Sanara Capital is a dedicated Health-Tech fund, established in 2023, specializing in Digital Health, Bio-Convergence, and Medical Devices. It focuses on Series A and B financing for Israeli-related startups globally. Leveraging its team, partners, and advisory board, Sanara Capital offers comprehensive support, accelerating portfolio companies' development and market penetration.
The firm's inception is spearheaded by Assaf Barnea, Founder and Managing Partner, a seasoned entrepreneur in healthcare innovation and venture development. Barnea's background includes founding medtech startup CardioSense and leading Kinrot Ventures. Sanara Capital evolved from Sanara Ventures, an earlier seed-stage platform launched in 2015 with Philips and Teva's support.
Sanara Capital primarily backs Israeli-related health technology startups, offering capital and strategic guidance. Inspired by "Sanare":to heal and restore harmony:the firm’s long-term vision integrates venture capital with entrepreneurial talent. Sanara Capital fosters transformative health solutions, guiding companies toward significant global impact.
Sanara Capital has 2 tracked investments across 2 companies. The latest tracked deal is $45.0M Series C in Ukko in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 8, 2026 | Ukko | $45.0M Series C | Israel Biotech Fund | Kira Peikoff, Fall Line Capital, Khosla Ventures |
| Mar 1, 2022 | CVAid Medical | $4.0M Series A | RAD BioMed | Philips |
